Cell
The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
1. A method for treating a cancerous disease, which comprises the step of administering a pharmaceutical composition which comprises a plurality of T cells or natural killer cells to a subject, wherein the T cells or natural killer cells express a chimeric antigen receptor (CAR) comprising a CD22-binding domain which comprises:
a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences:
CDR1
(SEQ ID NO: 27)
NYWIN,
CDR2
(SEQ ID NO: 28)
NIYPSDSFTNYNQKFKD,
and
CDR3
(SEQ ID NO: 29)
DTQERSWYFDV;
and
b) a light chain variable region (VL) having CDRs with the following sequences:
CDR1
(SEQ ID NO: 30)
RSSQSLVHSNGNTYLH,
CDR2
(SEQ ID NO: 31)
KVSNRFS,
and
CDR3
(SEQ ID NO: 32)
SQSTHVPWT,
wherein cancer cells of the cancerous disease express CD22.
2. A method according to claim 1 , wherein the CD22 binding domain comprises a VH domain having the sequence shown as SEQ ID NO: 35 or SEQ ID NO: 36, or a VL domain having the sequence shown as SEQ ID NO: 37 or SEQ ID NO: 38.
3. A method according to claim 1 , wherein the CD22 binding domain comprises the sequence shown as SEQ ID NO: 33 or SEQ ID NO: 34.
4. A method according to claim 1 , wherein the cancer is a B-cell malignancy.